Department of Radiation Oncology, University of Toronto, Toronto, ON.
Sunnybrook Odette Cancer Centre, Toronto, ON.
Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.
Written by:
Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S, Bristow RG. Are you the author?
Reference: Can Urol Assoc J. 2011 Apr;5(2):E31-5.
PubMed Abstract
PMID: 21470549
UroToday.com Prostate Cancer Section
